Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Immunity & Ageing : I & A|February 2, 2018
Ageing: from inflammation to cancerGiulia C Leonardi, Giulia Accardi, Roberto Monastero, et al.
International Journal of Oncology|June 26, 2020
Cutaneous melanoma and the immunotherapy revolution (Review)Giulia C Leonardi, Saverio Candido, Luca Falzone, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 31, 2017
Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung CancerGiulia C Leonardi, Geoffrey R Oxnard, Andrea Haas, et al.
International Journal of Oncology|March 14, 2018
Cutaneous melanoma: From pathogenesis to therapy (Review)Giulia C Leonardi, Luca Falzone, Rossella Salemi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2018
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune DisordersGiulia C Leonardi, Justin F Gainor, Mehmet Altan, et al.
Nature Communications|June 14, 2024
Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancersTaek-Chin Cheong, Ahram Jang, Qi Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 10, 2018
Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung CancerLorena Ostios-Garcia, Jennifer Faig, Giulia C Leonardi, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysisMark M Awad, Giulia C Leonardi, Sasha Kravets, et al.
NPJ Precision Oncology|April 9, 2026
Terminal T-cell exhaustion predicts tumor control independent of immunotherapy in ovarian cancerAnna Salvioni, Marie Michelas, Mathilde Del, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLCGonzalo Recondo, Magda Bahcall, Liam F Spurr, et al.
Pageof 2